<p>BioCryst Pharmaceuticals Inc. has issued an amendment to its previous Form 8-K filing, confirming the completion of its merger with Astria Therapeutics, Inc. As part of this update, BioCryst’s board has appointed Dr. Jill C. Milne to its Compensation and Science Committees, effective as of the merger closing date, January 23, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-000405), on January 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Reuters

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Astria Therapeutics

Health Care Select Sector SPDR

VG Health

BioCryst Pharma

BioCryst Pharmaceuticals Amends Board Appointment Disclosure